Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms

  • New Kisqali® (ribociclib)* overall survival subgroup analysis in HR+/HER2- advanced breast cancer (ABC) and additional Piqray® (alpelisib) data in patients in HR+/HER2- ABC patients with a PIK3CA mutation
  • Results from five-year adjuvant treatment study among BRAF+ melanoma patients taking Tafinlar®+Mekinist® (dabrafenib+trametinib) after surgical removal of their cancer
     
  • New data in non-small cell lung cancer, including efficacy and safety data for …
/by